ShopSpell

Accelerated Path to Cures [Hardcover]

$41.99     $54.99    24% Off      (Free Shipping)
100 available
  • Category: Books (Medical)
  • ISBN-10:  3319732374
  • ISBN-10:  3319732374
  • ISBN-13:  9783319732374
  • ISBN-13:  9783319732374
  • Publisher:  Springer
  • Publisher:  Springer
  • Binding:  Hardcover
  • Binding:  Hardcover
  • Pub Date:  01-Apr-2018
  • Pub Date:  01-Apr-2018
  • SKU:  3319732374-11-SPRI
  • SKU:  3319732374-11-SPRI
  • Item ID: 101252686
  • List Price: $54.99
  • Seller: ShopSpell
  • Ships in: 5 business days
  • Transit time: Up to 5 business days
  • Delivery by: Jul 04 to Jul 06
  • Notes: Brand New Book. Order Now.

Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.?

Chapter 1:?Introduction to Accelerated Path to Cures and Precision Medicine in Inflammatory Bowel Disease.- Chapter 2:?Computer-Aided Drug Discovery.- Chapter 3:?Preclinical Studies: Efficacy and Safety.- Chapter 4:?From Nutritional Immunology to Drug Development.- Chapter 5:?Development of Synthetic Patient Populations and?In Silico?Clinical Trials.

Dr. Josep Bassaganya-Riera is a serial entrepreneur and innovator who has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) at the Biocomplexity Institute of Virginia Tech since 2002. The NIMML tackles unsolved challenges in complex human diseases with unmet clinical needs. His research has received over $55 million in competitive R&D fundingl%
Add Review